Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer

Chinese Journal of Oncology

Volumn 33, Issue 5, 2011, Pages 385-387

  Cao, Ming ^a   Ma, Chen Kai ^a   Ma, Jun ^a   Chen, Hai Ge ^a   Xue, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer; Chemotherapy; Gemcitabine; Regional perfusion; Urinary bladder neoplasms

Indexed keywords

CAMPTOTHECIN; EPIRUBICIN; GEMCITABINE; MITOMYCIN;

ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEMATOLOGIC DISEASE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NON MUSCLE INVASIVE BLADDER CANCER; TREATMENT FAILURE; URINARY TRACT DISEASE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 80053391136     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2011.05.018     Document Type: Article

References (8)

1. Babjuk M, Oosterlinck W, Sylvester R, et al, EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol, 2008, 54:303-314.
2. Yates DR, Rouprêt M. Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. BJU Int, 2010, 106:162-167.
3. Grossman HB, O'Donnell MA, Cookson MS, et al. Bacillus Calmette-Guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol, 2008, 10:281-289.
4. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta Tl bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006, 49:466-477.
5. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 2000, 18:3068-3077.
6. Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmelte-Cuérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer; a multicenter prospective randomized trial. Cancer, 2010, 116:1893-1900.
7. Porena M, Del Zingaro M, Lazzeri M, et al. Bacillus Calmette- Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer; a randomised prospective study. Urol Int, 2010, 84:23-27.
8. Cho DY, Bae JH, Moon DG, et al. The effects of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin in superficial bladder cancer; a preliminary study. J Int Med Res, 2009, 37:1823-1830.